CynapseDx Company
CynapseDx develops analytical technologies for the detection of aggregated protein biomarkers in the blood of people suffering from a neurodegenerative disease, such as alzheimer or parkinson disease. They engage in oligomeric and aggregated forms of protein biomarkers and have demonstrated that our assays can measure these forms of biomarker proteins, when testing real patient blood samples.
Last Funding Type:
Seed
Funding Status:
Seed
Headquarters:
Liverpool, Liverpool, United Kingdom
Founded Date:
2010
Last Funding Date:
08-05-2015
Employee Number:
1-10
Investors Number:
1
Industry:
NeuroTech